Focused On-demand Library for Sulfate anion transporter 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9H2B4

UPID:

S26A1_HUMAN

Alternative names:

Solute carrier family 26 member 1

Alternative UPACC:

Q9H2B4; A8K9N2; Q7Z5R3; Q96BK0

Background:

Sulfate anion transporter 1, also known as Solute carrier family 26 member 1, plays a crucial role in the body's ability to transport sulfate anions. This protein facilitates the movement of various anions, including bicarbonate, thiosulfate, and oxalate, across cell membranes without the need for sodium. Its ability to mediate multiple anion exchanges, such as sulfate-thiosulfate, sulfate-hydrogencarbonate, and sulfate-oxalate, underscores its versatility and importance in maintaining anion balance within the body.

Therapeutic significance:

The association of Sulfate anion transporter 1 with calcium oxalate nephrolithiasis highlights its potential as a therapeutic target. Nephrolithiasis, characterized by the formation of calcium oxalate kidney stones, can lead to severe pain and renal complications. Understanding the role of Sulfate anion transporter 1 in this condition could open doors to novel therapeutic strategies aimed at preventing or treating kidney stones.